Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oxford BioDynamics ( (GB:OBD) ) just unveiled an announcement.
Oxford BioDynamics Plc announced it will release its financial results for the year ending September 30, 2024, on February 28, 2025. The announcement signifies a crucial update for stakeholders as it reflects the company’s operational performance and strategic positioning within the precision diagnostics industry. The company is known for its innovative genomics platform that enhances diagnostic precision and treatment predictions, supporting its market position and potential growth.
More about Oxford BioDynamics
Oxford BioDynamics Plc is an international biotechnology company focused on advancing personalized healthcare by developing precision clinical diagnostic tests for life-changing diseases. The company offers products such as the EpiSwitch PSE and EpiSwitch CiRT blood tests, which are based on its proprietary 3D genomic biomarker platform, EpiSwitch. These tests are designed to improve diagnostic accuracy and predict patient responses to treatments, particularly in areas like oncology and immuno-oncology.
YTD Price Performance: -66.67%
Average Trading Volume: 15,787,245
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £9.3M
See more data about OBD stock on TipRanks’ Stock Analysis page.